2. Metabolic Disease

Metabolic Disease

Metabolic Disease

Related Products

PDF 53.7 MB

Metabolic diseases is defined by a constellation of interconnected physiological, biochemical, clinical, and metabolic factors that directly increases the risk of cardiovascular disease, type 2 diabetes mellitus, and all cause mortality. Associated conditions include hyperuricemia, fatty liver (especially in concurrent obesity) progressing to nonalcoholic fatty liver disease, polycystic ovarian syndrome (in women), erectile dysfunction (in men), and acanthosis nigricans. Metabolic disease modeling is an essential component of biomedical research and a mandatory prerequisite for the treatment of human disease. Somatic genome editing using CRISPR/Cas9 might be used to establish novel metabolic disease models.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-50663
    MK 0893 870823-12-4 99.86%
    MK 0893 is a potent and selective glucagon receptor antagonist with an IC50 of 6.6 nM.
    MK 0893
  • HY-B1058
    Benfluorex hydrochloride 23642-66-2 99.85%
    Benfluorex hydrochloride (JP-992 hydrochloride) is a hepatic nuclear factor 4 alpha (HNF4α) activator.
    Benfluorex hydrochloride
  • HY-101981
    Uridine 5'-monophosphate 58-97-9
    Uridine 5'-monophosphate (5'-Uridylic acid) is an orally active mitochondrial ATP-dependent potassium channel activator that has a protective effect on the heart. Uridine 5'-monophosphate can promote the synthesis of CDP-choline and induce apoptosis in intestinal epithelial cells, which is beneficial for gut development and reduces diarrhea.
    Uridine 5'-monophosphate
  • HY-148476
    Tri-GalNAc-DBCO 98.05%
    Tri-GalNAc-DBCO is a synthetic ligand composed of three GalNAc units linked to DBCO. Tri-GalNAc-DBCO can undergo strain-promoted alkyne-azide cycloaddition (SPAAC) reactions with molecules containing an azide group. Tri-GalNAc-DBCO specifically binds to the asialoglycoprotein receptor (ASGPR). Tri-GalNAc-DBCO directs the conjugated molecule to the lysosome for degradation via receptor-mediated endocytosis. Tri-GalNAc-DBCO can be used in the study of liver-related diseases.
    Tri-GalNAc-DBCO
  • HY-13290
    KN-62 127191-97-3 99.45%
    KN-62 is a selective and reversible inhibitor of calmodulin-dependent protein kinase II (CaMK-II) with a Ki of 0.9 μM for rat brain CaMK-II. KN-62 directly binds to the calmodulin binding site of CaMK-II. KN-62 displays noncompetitive antagonism at P2X7 receptors in HEK293 cells, with an IC50 value of approximately 15 nM.
    KN-62
  • HY-B1232
    Metyrapone 54-36-4 99.84%
    Metyrapone (Su-4885) is a potent and orally active 11β-hydroxylase inhibitor and an autophagy activator, also inhibits the production of aldosterone. Metyrapone inhibits synthesis of endogenous adrenal corticosteroid, decreases glucocorticoid levels, and also affects behavior and emotion. In addition, Metyrapone increases the efficiency of autophagic process via downregulation of mTOR pathway, and interacts with Pseudomonas putida cytochrome P-450. Metyrapone can be used for researching Cushing's syndrome and depression.
    Metyrapone
  • HY-N2364
    Arecoline 63-75-2 99.84%
    Arecoline, a naturally occurring psychoactive alkaloid, is a partial agonist of nicotinic and muscarinic acetylcholine receptor. Arecoline exhibits stimulation, alertness, anxiolysis and anti-parasitic effects. Arecoline also can induce oxidative stress.
    Arecoline
  • HY-B0401
    Tolbutamide 64-77-7 ≥98.0%
    Tolbutamide is an orally active KATP inhibitor. Tolbutamide inhibits cell proliferation, stimulates exocytosis of glucagon and reduces fetal lethality of mice. Tolbutamide can be used in the research of diabete.
    Tolbutamide
  • HY-W012875
    3-Nitropropanoic acid 504-88-1 ≥98.0%
    3-Nitropropanoic acid (β-Nitropropionic acid) is an irreversible and orally active inhibitor of succinate dehydrogenase. 3-Nitropropanoic acid exhibits potent antimycobacterial activity with a MIC value of 3.3 μM. 3-Nitropropanoic acid can induce cell apoptosis.
    3-Nitropropanoic acid
  • HY-B0607
    Nitisinone 104206-65-7 99.93%
    Nitisinone is an orally active, competitive and reversible 4-hydroxyphenylpyruvate dioxygenase (4-HPPD) inhibitor with an IC50 of 173 nM. Nitisinone promotes tyrosine accumulation in a dose-dependent manner. nitisinone can be used in studies of hereditary tyrosinemia type 1 (HT-1) (a rare genetic disorder) and albinism.
    Nitisinone
  • HY-N7033
    UDP-glucuronic acid trisodium 63700-19-6 ≥98.0%
    UDP-​glucuronic acid trisodium (Uridine-5'-diphosphoglucuronic acid trisodium salt) is a critical precursor for essential glycoconjugates across biological kingdoms, ranging from mammalian glycosaminoglycans and plant cell wall polysaccharides to bacterial capsule glycoglycerolipids.
    UDP-glucuronic acid trisodium
  • HY-113329
    Guanidinoethyl sulfonate 543-18-0 ≥98.0%
    Guanidinoethyl sulfonate (Taurocyamine) is an orally available, blood-brain permeable competitive inhibitor of taurine transporters and a competitive antagonist of glycine receptors (GlyR) (IC50=565 μM). Guanidinoethyl sulfonate has both weak agonist and antagonist effects on GABAA receptors. Guanidinoethyl sulfonate inhibits taurine transmembrane transport and competitively binds to the GlyR ligand binding domain, thereby blocking glycine-mediated chloride influx, and may regulate brain pH to exert neuroprotective effects. Guanidinoethyl sulfonate can be used for neuroprotection studies of ischemic brain injury.
    Guanidinoethyl sulfonate
  • HY-121835
    GLP-1R agonist 2 281209-71-0 99.94%
    GLP-1R agonist 2 (compound 2) is an effective GLP-1R agonist that exerts its activating effect by forming hydrogen bonds with the Tyr42, Cys71, and Ser84 residues of GLP-1R. GLP-1R agonist 2 has the potential for research in metabolic diseases such as type 2 diabetes and obesity.
    GLP-1R agonist 2
  • HY-12689
    Mitapivat 1260075-17-9 99.84%
    Mitapivat (AG-348) is an orally active pyruvate kinase allosteric activator. Mitapivat increases enzymatic activity, protein stability, and ATP levels over a broad range of PKLR genotypes, shows the potential to restore the activity of PK (pyruvate kinase)-deficient glycolytic pathways. Mitapivat can be used in study of PK deficiency.
    Mitapivat
  • HY-119254
    BAY-850 2099142-76-2 98.33%
    BAY-850 is a potent and isoform selective ATPase family AAA domain-containing protein 2 (ATAD2) inhibitor, with an IC50 of 166 nM.
    BAY-850
  • HY-D0227
    THAM 77-86-1 ≥98.0%
    THAM (Tris) is a biologically inert amino alcohol of low toxicity, which buffers carbon dioxide and acids in vitro and in vivo. THAM is an effective amine compound for pH control in the physiological range.
    THAM
  • HY-N0752
    Scutellarein 529-53-3
    Scutellarein is a natural flavonoid compound with anti-inflammatory effects.
    Scutellarein
  • HY-Y1636
    Fmoc-Arg(Pbf)-OH 154445-77-9 ≥98.0%
    Fmoc-Arg(Pbf)-OH is an arginine derivative containing amine protecting group Fmoc. Fmoc-Arg(Pbf)-OH is a building block for the introduction of Arg into SPPS (Solid-Phase Peptide Synthesis).
    Fmoc-Arg(Pbf)-OH
  • HY-111174
    Diprotin A 90614-48-5 99.58%
    Diprotin A (Ile-Pro-Ile) is an inhibitor of dipeptidyl peptidase IV (DPP-IV).
    Diprotin A
  • HY-141669
    BCAT-IN-2 1800024-45-6 99.07%
    BCAT-IN-2 is a potent, selective and orally active inhibitor of mitochondrial branched-chain aminotransferase (BCATm), with a pIC50 of 7.3. BCAT-IN-2 shows selectivity for BCATm over BCATc (pIC50=6.6). BCAT-IN-2 can be used for the research of obesity and dislipidema.
    BCAT-IN-2
Cat. No. Product Name / Synonyms Application Reactivity